arrow
S

Sara Elena Rebuzzi

ospedale molinette
H指数:25
被引数:2,034

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

转移性透明细胞肾细胞癌一线免疫联合治疗中的分子生物标志物:Meet-URO小组对III期随机临床试验的系统综述

2026-08-260
OAAI
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study

转移性肾细胞癌一线治疗方案的选择模式:Meet-URO 33—REGAL研究的真实世界分析

2026-08-200
PRE
Gene expression analyses of immune tumor microenvironment in advanced renal cell carcinoma patients based on response to immunotherapy (Meet-URO 18 I-TME study)

基于免疫治疗反应的晚期肾细胞癌患者免疫肿瘤微环境基因表达分析(Meet-URO 18 I-TME研究)

2026-08-190
OA
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study

可解释机器学习预测转移性肾细胞癌免疫治疗结局——Meet-URO 15-AI研究

2026-07-020
OAAI
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations

在晚期肾细胞癌中优化预后:国际真实世界数据验证Meet-URO评分在一线免疫治疗联合方案中的应用

2026-05-200
OA
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25

转移部位和数量可预测avelumab维持治疗晚期尿路上皮癌的结局:meet-URO 25研究的结果

2026-02-140
OAAI
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感型前列腺癌最佳治疗方法: 系统评价和网络荟萃分析

2025-11-170
OA
IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations

IUC24394-87 接受一线免疫联合治疗的转移性肾细胞癌患者Meet-URO评分更新

2025-08-290
OAAI
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience
2025-01-310
OAAI
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)

转移性肾细胞癌患者的国际多中心真实世界注册表-meet-uro 33研究 (REGAL研究)

2024-06-246
OAAI
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

接受免疫治疗的晚期肾细胞癌患者的肿瘤微环境分析 (Meet-URO 18研究)

2024-06-120
PRE
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

PARP抑制剂和雄激素受体信号抑制剂联合治疗转移性前列腺癌: 定量合成和荟萃分析

2024-04-0110
OA
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

转移性前列腺癌老年患者日常生活的工具性活动: 来自meet-URO网络坚持前瞻性研究的结果

2024-02-281
OAAI